2 hours ago
1
georgeclerk
HSBC has upgraded Eli Lilly (NYSE:LLY) to Hold from Reduce, noting the latest Phase 3 trial success of the U.S. pharma giant's once-daily weight loss pill orforglipron, developed with Chugai (OTCPK:CHGCF) (OTCPK:CHGCY).
Data from LLY’s Phase 3 ATTAIN-2 trial indicated
© FBT Company 2025. All rights are reserved
English (US) ·